Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.
Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.
复制标题
DOI：
10.3389/fonc.2014.00191
复制
发表时间：
2014
影响因子：
4.7
通讯作者：
Diallo JS
中科院分区：
文献类型：
--
作者：
Forbes NE;Krishnan R;Diallo JS
溶瘤病毒（OV）不仅通过直接裂解杀死癌细胞，而且还产生显著的抗肿瘤免疫应答，这允许延长癌症控制并且在某些情况下治愈。如何最好地激发这种效应是OV领域中深入研究的主题。虽然几个研究组已经显示细胞先天性抗病毒免疫应答的药理学操作可以改善病毒溶瘤和扩散，但越来越清楚的是，药理学试剂也可以影响由OV和相关肿瘤疫苗接种策略产生的抗肿瘤免疫应答。本文综述了近年来利用药理学药物提高OVs活性及其产生抗肿瘤免疫应答的研究进展。
Oncolytic viruses (OVs) not only kill cancer cells by direct lysis but also generate a significant anti-tumor immune response that allows for prolonged cancer control and in some cases cures. How to best stimulate this effect is a subject of intense investigation in the OV field. While pharmacological manipulation of the cellular innate anti-viral immune response has been shown by several groups to improve viral oncolysis and spread, it is increasingly clear that pharmacological agents can also impact the anti-tumor immune response generated by OVs and related tumor vaccination strategies. This review covers recent progress in using pharmacological agents to improve the activity of OVs and their ability to generate robust anti-tumor immune responses.